ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021
Is diabetes associated with increased pathological burden in Alzheimer's disease?
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Dementia in type 2 diabetes: risk factors, disease processes and opportunities for prevention across the lifespan.Diabetologia · 2026Review
- Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications.The journal of prevention of Alzheimer's disease · 2026Review
- Association of type 2 diabetes treatment status with in vivo biomarkers of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Synergistic effects of multiple pathological processes on Alzheimer's disease risk: Evidence for age-dependent stroke interactions.The journal of prevention of Alzheimer's disease · 2025Article
- Article
- Permutations of cerebrovascular pathologies in older adults with and without diabetes.Cerebral circulation - cognition and behavior · 2025Article
- Insulin resistance induces earlier initiation of cognitive dysfunction mediated by cholinergic deregulation in a mouse model of Alzheimer's disease.Aging cell · 2023Article
- Hypericin as a potential drug for treating Alzheimer's disease and type 2 diabetes with a view to drug repositioning.CNS neuroscience & therapeutics · 2023Article
- Prediction of neuropathologic lesions from clinical data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Amyloid β-Peptide Effects on Glucose Regulation Are Dependent on Apolipoprotein E Genotype.eNeuro · 2023Article
- Potential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Review
- The Effects of Dietary Advanced Glycation End-Products on Neurocognitive and Mental Disorders.Nutrients · 2022Review
- To understand the diabetes-dementia association, frailty may prove more fruitful than neuropathology.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Is diabetes associated with increased pathological burden in Alzheimer's disease?Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
introductionWe examined the association between Alzheimer's disease (AD) and type 2 diabetes mellitus (DM) and hypothesized that diabetes is associated with an increased pathological burden in clinically and pathologically diagnosed AD.
methodsAll data were obtained from the Uniform Data Set (UDS) v3, the Neuropathology Data Set, and the Researcher's Data Dictionary-Genetic Data from the National Alzheimer's Coordinating Center. The dataset (37 cases with diabetes and 1158 cases without) relies on autopsy-confirmed data in clinically diagnosed AD patients who were assessed for diabetes type in form A5 or D2 during at least one visit. Differences in scores were explored using a general linear model. Effect sizes were calculated using sample means and standard deviations (Cohen's
resultsThe presence of diabetes was associated with a lower Thal phase of amyloid plaques (A score; 4.6 ± 0.79 vs. 4.3 ± 0.85, DISCUSSION: This pilot study found a significantly lower Thal phase of amyloid plaques and Braak stage for neurofibrillary degeneration in AD-confirmed individuals with diabetes compared to those without. Thus type 2 DM is not associated with increased AD pathology in clinically and pathologically confirmed cases of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.